Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy

Leukemia. 2020 Aug;34(8):2271-2275. doi: 10.1038/s41375-020-0749-5. Epub 2020 Feb 18.

¹ Department of Paediatric Haematology, Oncology and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK. [email protected].
² Department of Hematology and Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
³ Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA.
⁴ Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany.
⁵ Department of Child and Adolescent Cancer, Gustave Roussy, Paris, France.
⁶ Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
⁷ Department of Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
⁸ Department of Pediatric Oncology, Gazi University, Ankara, Turkey.
⁹ Department of Pediatric Hematology and Oncology, Ankara University, Ankara, Turkey.
¹⁰ Clinical Oncology, Janssen R&D LLC, High Wycombe, UK.
¹¹ Clinical Pharmacology, Janssen R&D LLC, San Diego, CA, USA.
¹² Clinical Oncology, Janssen R&D LLC, Raritan, NJ, USA.
¹³ Pharmacometrics, Janssen R&D LLC, Beerse, Belgium.
¹⁴ Department of Pediatrics, Medicine, Pathology, Microbiology and Immunology and Cell Biology and Anatomy, New York Medical College, Valhalla, NY, USA.

No abstract available

Publication types